Source link : https://www.newshealth.biz/health-news/novel-monoclonal-antibody-shows-promise-in-ulcerative-colitis/
Significantly more patients with moderately to severely active ulcerative colitis achieved clinical remission with the investigational monoclonal antibody tulisokibart compared with placebo, a randomized phase II trial showed. Among 135 adults, 26% achieved clinical remission at 12 weeks with tulisokibart compared with 1% of those receiving placebo (P
Author : News Health
Publish date : 2024-09-25 21:00:00
Copyright for syndicated content belongs to the linked Source.
Categories